PMID- 15667625
OWN - NLM
STAT- MEDLINE
DCOM- 20050527
LR  - 20161124
IS  - 1397-3142 (Print)
IS  - 1397-3142 (Linking)
VI  - 9
IP  - 1
DP  - 2005 Feb
TI  - Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning 
      regimen for secondary acute myelogenous leukemia.
PG  - 122-6
AB  - We report the case of a 15-yr-old girl who developed secondary acute myelogenous 
      leukemia (AML) 4 yr after completion of therapy for metastatic Ewing sarcoma 
      (primary right acetabulum with metastatic disease to the lungs). Peripheral blood 
      stem cells were collected after the second cycle of chemotherapy with the plan 
      for future consolidation with high-dose chemotherapy and autologous stem cell 
      rescue; however, because of the patient's excellent response to chemotherapy and 
      surgery, therapy was completed without the need for high-dose chemotherapy. No 
      human leukocyte antigen (HLA)-matched related donor was available for a bone 
      marrow transplant. Because of previous lung radiation, high-dose samarium [30 
      mCi/kg of samarium-153 ethylenediaminetetramethylenephosphonate ((153)Sm-EDTMP) 
      day -14] and melphalan (140 mg/m(2) day -2) were chosen as the conditioning 
      regimen to avoid potential lung complications. The patient received an infusion 
      of 6.1 x 10(8)/kg mononuclear autologous cells on day 0. She achieved engraftment 
      on day +23. Three years after transplantation, she continues to have complete 
      remission. Samarium and melphalan constitute a well-tolerated regimen with 
      potential antileukemic activity.
FAU - Rodriguez, Vilmarie
AU  - Rodriguez V
AD  - Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN 55905, USA. 
      rodriguez.vilmarie@mayo.edu
FAU - Erlandson, Linda
AU  - Erlandson L
FAU - Arndt, Carola A S
AU  - Arndt CA
FAU - Wiseman, Gregory A
AU  - Wiseman GA
FAU - Anderson, Peter M
AU  - Anderson PM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Denmark
TA  - Pediatr Transplant
JT  - Pediatric transplantation
JID - 9802574
RN  - 0 (Organometallic Compounds)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Radioisotopes)
RN  - 42OD65L39F (Samarium)
RN  - 745X144DZY (samarium Sm-153 lexidronam)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adolescent
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - *Melphalan
MH  - Organometallic Compounds/*therapeutic use
MH  - Organophosphorus Compounds/*therapeutic use
MH  - *Radioisotopes
MH  - *Samarium
MH  - Stem Cell Transplantation
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Autologous
EDAT- 2005/01/26 09:00
MHDA- 2005/05/28 09:00
CRDT- 2005/01/26 09:00
PHST- 2005/01/26 09:00 [pubmed]
PHST- 2005/05/28 09:00 [medline]
PHST- 2005/01/26 09:00 [entrez]
AID - PTR248 [pii]
AID - 10.1111/j.1399-3046.2005.00248.x [doi]
PST - ppublish
SO  - Pediatr Transplant. 2005 Feb;9(1):122-6. doi: 10.1111/j.1399-3046.2005.00248.x.